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OBJECTIVES: The aim of this prospective study was to compare changes in lipid metabolism and nutritional status
after either 6 and 12 months of follow-up in subjects with lipodystrophy syndrome after traditional lifestyle therapy
with or without fibric acid analogue intervention (bezafibrate and clofibrate).
METHODS: Food intake, alterations in body composition and metabolic abnormalities were assessed in subjects with
lipodystrophy syndrome at the beginning of the study. The nutritional status and metabolic alterations of the
subjects were monitored, and the subjects received nutritional counseling each time they were seen. The subjects
were monitored either two times over a period no longer than six months (Group A; n = 18) or three times over a
period of at least 12 months (Group B; n = 35). All of the subjects underwent nutrition counseling that was based
on behavior modification. The fibric acid analogue was only given to patients with serum triglyceride levels above
400 mg/dL.
RESULTS: After six months of follow-up, Group A showed no alterations in the experimental parameters. After
twelve months, there was a decrease in serum triglyceride levels (410.4 ¡ 235.5 vs. 307.7 ¡ 150.5 mg/dL, p, 0.05)
and an increase in both HDLc levels (37.9¡ 36.6 vs. 44.9¡ 27.9 mg/dL, p,0.05) and lean mass (79.9¡ 7.8 vs. 80.3¡
9.9 %, p, 0.05) in Group B.
CONCLUSION: After one year of follow-up (three sessions of nutritional and medical counseling), the metabolic
parameters of the subjects with lipodystrophy improved after traditional lifestyle therapy with or without fibric acid
analogue intervention.
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INTRODUCTION
The treatment of human immunodeficiency virus (HIV)
infection with HAART (highly active antiretroviral therapy),
particularly the inclusion of protease inhibitors, was a major
advance in improving the survival of HIV-positive indivi-
duals. However, this therapy is associated with a lipody-
strophy syndrome, which involves the wasting of adipose
tissue from peripheral sites with the preservation of central
adipose depots, hyperlipidemia, impaired glucose tolerance
and overt type 2 diabetes.1
The consumption of a low-glycemic-index diet that is also
low in saturated fats and high in vitamins, fiber, mono-
unsaturated fatty acids and polyunsaturated fatty acids may
decrease triglyceride and low-density lipoprotein choles-
terol levels in HIV-negative and HIV-positive subjects with
cardiovascular risk factors.2-5 Twenty percent of persons
with HIV who are on the HAART have a 10-year risk of
developing coronary heart disease of 10% or higher, and
this risk may also be associated with inadequate dietary
habits.6 The nutritional strategies used to manage AIDS-
related lipodystrophy syndrome are not well described, and
fibrates have been shown to have a significant effect on the
treatment of diet-resistant hyperlipidemia. Fibrates are
carboxylic acids that are used in the treatment of dyslipi-
demia because they moderately lower LDLc levels, sig-
nificantly lower triglyceride levels and raise HDLc levels.
Micronized fenofibrate is a fibrate derivative that was
approved in February 1998 by the Food and Drug
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Administration (FDA).7 Examples of fibrates include cipro-
fibrate, bezafibrate, etofibrate, beclofibrate and pirifibrate.
The present study aimed to confirm the hypothesis that,
with the same medical and nutritional counseling, twelve
months of follow-up is more effective than six months of
follow-up in both the treatment of hyperlipidemia and the
improvement of nutritional status in HIV-1-positive patients
with lipodystrophy.
MATERIALS AND METHODS
Using a computer program, 53 HIV-1-positive8,9 adult
patients with lipodystrophy syndrome were randomly
recruited from the outpatient clinic of infectious diseases
at the School Hospital of the University of Sa˜o Paulo,
Ribeira˜o Preto, Brazil, which provides treatment for 240
subjects annually.
Criteria for inclusion in the study included confirmed
HIV infection and the use of continuous HAART with at
least one protease inhibitor (PI) and two nucleoside reverse
transcriptase inhibitors (NRTI) for $ 2 months. All of the
patients provided written informed consent as approved by
the local Institutional Review Board.
The nutritional assessments and laboratory analyses were
performed at baseline (during the first visit), after 6 months
and after 12 months. The weight and height of each
participant were measured using standard methods that
have been previously validated.10,11 Body mass index [BMI
– weight (kg)/ height2 (meters)] was calculated by the
standard formula using height and weight. The mid-arm
circumference, subscapular skinfold and triceps skinfold
were also measured as a reflection of lean body and fat
mass.10 Lipid profiles were measured using standard
clinical laboratory methods.12
The impedance bioelectric technique was performed with
a BIA RJL System 101QH (BIA-101A; RJL Systems, Clinton
Township, MI) to measure body composition.
The nutritional and medical counseling was based on
recall of food intake, representative examples of each
patient’s usual diet and encouragement to consume a low-
glycemic-index diet that was also low in saturated fat
(, 10% total energy) and high in vitamins, fiber (25 g/day),
monounsaturated fatty acids (. 10% total energy), and
polyunsaturated fatty acids (10% total energy). The counsel-
ing was based on behavior modification13 and took
approximately 2 hours. Fibrate analogues were adminis-
tered to the subjects with hyperlipidemia whose triglyceride
levels were . 400 mg/dl. The subjects were divided into
two groups according to the length of follow-up, and each
subject attended nutritional and medical counseling ses-
sions either two times over a period no longer than six
months (Group A; n = 18) or three times over a period of at
least 12 months (Group B; n = 35).
Energy and nutrient intake was analyzed using a
Brazilian computerized dietary database (NUTRI-EPM-
Escola Paulista de Medicina).
Demographic data and physical activity level were also
recorded in the database.
Statistical analyses were performed using SPSS 10.0
software. Continuous variables with normal distributions
were expressed as mean ¡ standard deviation, and com-
parisons across groups were done by unpaired t-test for
these variables. The nonparametric Mann-Whitney test was
used to compare variables with non-normal distributions,
which are represented by the median and range. Paired t-
tests for means or Wilcoxon signed rank tests (if data were
not normally distributed) were used to compare the
variables at two different time points. Nominal data were
analyzed by either the x2 or Fisher exact test. P values of #
0.05 were considered statistically significant.
RESULTS
The rate of subject compliance was 100%. Nutritional
status and metabolic alterations were monitored, and the
subjects received nutritional counseling at every appoint-
ment. The 53 subjects were divided into two groups: Group
(A) consisted of subjects who were monitored two times
over a period no longer than six months (n = 18), and
Group (B) consisted of subjects who were monitored three
times over a period of at least 12 months (n = 35). The
majority of the subjects were men (Group A = 76%; Group
B = 80%), and the groups were age-matched (Group A =
47.1 ¡ 11.1; Group B = 43.3 ¡ 7.9 years of age; p . 0.05).
None of the subjects claimed to exercise regularly. All of the
subjects had serum triglyceride levels that were greater than
or equal to 150 mg/dl, but subjects were only given a fibrate
if their serum levels were above 400 mg/dl. Six patients
(33.33%) in Group A received fibrates (bezafibrate or
clofibrate), and twelve (34.3%) patients in Group B received
fibrates (bezafibrate or clofibrate) (p = 0.94).
There were no changes in the anthropometric and
metabolic parameters of Group A. In Group B, the
triglyceride levels were significantly lower and the HDL
levels and lean mass were significantly higher at the end of
the study (Table 1). No statistically significant differences in
food intake were observed between the two groups (Table 2).
DISCUSSION
The findings of our study suggest that HIV-positive
patients with lipodystrophy who were followed for twelve
months (three nutritional and medical counseling sessions)
in an outpatient clinic for infectious diseases showed an
improvement in serum triglyceride and HDLc levels and an
increase in lean mass compared to HIV-positive patients
with lipodystrophy who received the same multidisciplin-
ary approach but were followed for only six months (two
nutritional and medical counseling sessions). These results
cannot be attributed to differences in either food intake or
the percentage of subjects taking a fibrate because there
were no differences in these variables between the two
groups.
The levels of total cholesterol and LDL–cholesterol did
not significantly improve during the study. Some possible
reasons for this lack of effect include the pathophysiology of
lipid abnormalities in HIV-infected patients14 and the effects
of antiretrovirals, which may have limited the effects of
lifestyle modification on lipid metabolism.
The lipid profiles of HIV-positive patients are character-
ized by low levels of HDL (high density lipoprotein) and
high levels of both LDL (low density lipoprotein) cholesterol
and total cholesterol; this type of lipid profile predisposes
patients to atherogenesis. Some studies have shown that the
incidence of cardiovascular events in patients with HIV
infection who are on HAART is higher than that in the
general population.15 Diet therapy is recommended for
primary prevention and control of dyslipidemia in HIV-
positive patients on HAART.16
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Our study failed to reveal any statistically significant
changes in food intake after either 6 or 12 months of follow-
up. These results could be partially explained by either an
under or overestimation of food intake resulting from
memory bias and an inability to diet.17 Similar results were
reported in another study in which no differences in dietary
intake parameters were observed between a group receiving
weekly one-on-one counseling sessions and a control
group.18
As has been reported previously,19,20 no anthropometric
changes were detected during the present study. More
sophisticated techniques, such as DEXA or CT, would have
provided a clearer view of the relative changes in body
tissue composition over time.
Our results revealed a significant alteration in free-fat
mass. Other variables, such as physical activity level, may
also have contributed to this finding, but none of the
subjects claimed to exercise regularly. The significant
alterations in body composition in patients with HIV were
characterized by bioelectrical impedance analysis (BIA), but
this form of analysis may not accurately assess body
composition in patients with lipodystrophy. A recent
longitudinal study reported no significant differences in
estimates of changes in fat mass.22
A change in diet alone can markedly improve elevated
triglyceride levels, but these levels are unlikely to return to
normal without interventional counseling. In Brazil, lipid-
lowering agents, such as gemfibrozil and fenofibrate, have
been used to treat isolated or severe hypertriglyceridemia
and/or elevated LDL and total cholesterol levels in patients
who do not respond to modification of antiretroviral
therapy or therapeutic lifestyle changes, as well as in
patients in whom such modifications are not appropriate.23
Fibrates, such as gemfibrozil, increase the activity of
lipoprotein lipase, resulting in a reduction in triglyceride
levels.24 Gemfibrozil and other fibrates activate peroxisome
proliferator-activated receptors (PPARs), which allows these
drugs to modulate lipoprotein metabolism.25
Several studies have found that, when used for primary
prevention, fibrate therapy leads to a 71% decrease in residual
risk, leaving only a 3.8% major CVD event rate. Others studies
have shown that fibrate therapy, when used in primary
prevention, reduces the residual risk by 19% to 8.9%.26,27
The difference in sample size between the two groups
was not a confounding variable because, when we did
statistical analyses that randomly excluded subjects in
Group B, the results were the same (data not shown).
The present study suggests that, with the same nutritional
and medical treatment, patients who were followed for at
least twelve months showed a stronger improvement in
their lipid profiles than those who were followed for only
six months. Confounding clinical and social issues, such as
Table 1 - Anthropometric and biochemical parameters of HIV-positive subjects with lipodystrophy.
Parameters
Group A Group B
Baseline End of study Baseline End of study
BMI (kg/m2) 26.9 ¡ 6.1 26.8 ¡ 6.2 24.5 ¡ 3.6 24.1 ¡ 3.6
Mid-arm circumference (cm) 29.3 ¡ 5.09 29.6 ¡ 4.7 28.7 ¡ 3.9 28.6 ¡ 3.4
Triceps skinfold (mm) 13.4 ¡ 11.4 12.7 ¡ 10.2 9.4 ¡ 4.7 10.2 ¡ 6.1
Waist circumference (cm) 92.9 ¡ 13.2 92.1 ¡ 11.2 87.5 ¡ 7.7 88.4 ¡ 7.0
Fat mass (%) 23.6 ¡ 11.0 24.2 ¡ 10.3 20.0 ¡ 7.8 19.0 ¡ 8.2
Lean mass (%) 76.4 ¡ 11.0 75.8 ¡ 10.3 79.9 ¡ 7.8 80.3 ¡ 9.9**
Glucose (mg/dL) 112.9 ¡ 50.9 109.4 ¡ 49.2 99.5 ¡ 21.9 97.9 ¡ 15.2
TC (mg/dL) 239.1 ¡ 53.6 221.4 ¡ 59.5 222.1 ¡ 66.4 209.8 ¡ 56.0
HDLc (mg/dL) 38.1 ¡ 11 44.5 ¡ 16.1 37.9 ¡ 36.6 44.9 ¡ 27.9**
LDLc (mg/dL) 130.6 ¡ 53.8 133.9 ¡ 56.9 141.4 ¡ 86.4 112.1 ¡ 49.0
TG (mg/dL) 416.8 ¡ 267.2 303.3 ¡ 140.6 410.4 ¡ 235.5 307.7 ¡ 150.5**
Group A: Subjects were monitored two times over a period no longer than six months (n = 18); Group B: Subjects were monitored three times over a
period of at least 12 months (n= 35).
**p,0.05 for differences between time points in Group B only; BMI = body mass index; TC = total cholesterol; TG = triglycerides; HDL = high density
lipoprotein; LDL = low density lipoprotein
Table 2 - Food intake parameters of HIV-positive subjects with lipodystrophy.
Parameters*
Group A Group B
Baseline End of study Baseline End of study
Energy (kcal) 1852 ¡ 799 1623 ¡ 732 1819 ¡ 733 1972 ¡ 837
Protein (g) 101.7 ¡ 41.4 80.7 ¡ 42.5 86.9 ¡ 38.5 102.8 ¡ 54.1
Lipids (g) 66.7 ¡ 41.3 54.2 ¡ 30.4 61.8 ¡ 38.9 63.6 ¡ 39.5
Saturated fat (mg) 26 ¡ 18.9 20 ¡ 11.7 21.2 ¡ 14.5 22.1 ¡ 14.5
Polyunsaturated fat (mg) 6.0 ¡ 3.8 4.5 ¡ 3.5 5.8 ¡ 5.6 6.8 ¡ 6.2
Monounsaturated fat (mg) 6 (2-28) 6 (0-14) 7 (0-53) 6 (0-78)
Cholesterol (mg) 216 ¡ 102 214 ¡ 116 238.0 ¡ 204.0 260.4 ¡ 158.2
The data were collected during consultations and were based on recall of food intake that was representative of the subject’s usual diet. Data were
analyzed using a Brazilian computerized dietary database (NUTRI – EPM – Escola Paulista de Medicina).
*p.0.05 between groups and over time. Continuous variables with normal distributions were expressed as a mean ¡ standard deviation; in this case,
comparisons across groups were done using an unpaired t-test. Nonparametric Mann-Whitney tests were used to compare variables with non-normal
distributions, which are expressed as a median and range. Paired t-tests for means or Wilcoxon signed rank tests (if data were not normally distributed)
were used to compare variables at two time points.
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medication interactions, comorbidities, lipodystrophy, food
insecurity, aging, and other related conditions, further
complicate disease management. Despite a greater under-
standing of the mechanisms of HIV/AIDS and its impact on
the body, as well as the development of new treatments, the
wide range of populations affected make the management
of chronic HIV infection a complex and demanding issue.28
CONCLUSIONS
Our results suggest that subjects with lipodystrophy
syndrome show an improvement in metabolic parameters
after nutritional counseling with or without concurrent
treatment with a fibrate analogue after one year of follow-
up. Our experimental design did not allow us to distinguish
between the effects of these two variables on the metabolic
profile. Considering that there was no change in food intake
during the follow-up period in either group and that the
proportion of patients using fibrate was the same in both
groups, it is possible that the effects were due to the
combination of the two treatments for a longer period of
time. However, studies investigating this issue are scarce.
Further double-blind, randomized clinical trials are con-
tributing to clarify the recommendations for nutritional and
medical treatment of lipodystrophy syndrome.
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